✦ LIBER ✦

A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis

Book ID: 116588288
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 49 KB
Volume: 66
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2011.11.047

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Masitinib for the treatment of canine at

Masitinib for the treatment of canine atopic dermatitis: a pilot study

✍ Jenise Daigle; Alain Moussy; Colin D. Mansfield; Olivier Hermine 📂 Article 📅 2009 🏛 Springer Netherlands 🌐 English ⚖ 155 KB

Treatment of psoriatic arthritis in a ph

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

✍ Kavanaugh, Arthur (author);Mease, Philip J. (author);Gomez-Reino, Juan J. (autho 📂 Article 📅 2014 🏛 BMJ Publishing Group 🌐 English ⚖ 543 KB

Treatment of psoriatic arthritis in a ph

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

✍ Kavanaugh, Arthur (author);Mease, Philip J. (author);Gomez-Reino, Juan J. (autho 📂 Article 📅 2014 🏛 BMJ Publishing Group 🌐 English ⚖ 543 KB

Treatment of psoriatic arthritis in a ph

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

✍ Kavanaugh, Arthur (author);Mease, Philip J. (author);Gomez-Reino, Juan J. (autho 📂 Article 📅 2014 🏛 BMJ Publishing Group 🌐 English ⚖ 543 KB

## Objectives Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying anti

A pilot study of emollient therapy for t

A pilot study of emollient therapy for the primary prevention of atopic dermatitis

✍ Eric L. Simpson; Trista M. Berry; Peter A. Brown; Jon M. Hanifin 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 464 KB

Improvements in patient-reported outcome

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

✍ Vibeke Strand, David Fiorentino, ChiaChi Hu… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 457 KB